Laurus Labs Limited

BSE: 540222 NSE: LAURUSLABS
Laurus Labs Limited - pharma in Anakapalle, Andhra Pradesh, India. FY 2026 financials & compliance.
CIN L24239AP2005PLC047518 Incorporated 19 September 2005 ROC Vijayawada HQ Anakapalle, Andhra Pradesh, India
Active Listed - NSE: LAURUSLABS · BSE: 540222 Public Limited Company pharma
Data last updated
Market Cap
₹1,09,478 Cr
LAURUSLABS · NSE
Share Price
₹1,989.10
-1.83% today
Revenue
₹6,813 Cr
FY 2025-26 · +11.9% YoY
EBITDA
₹1,778 Cr
Margin 26.1%
Net Profit
₹894 Cr
FY 2025-26 · +216.3% YoY
P/E (TTM)
99.2x
P/B 20.5x
ROE
18.2%
ROCE 16.7%
Debt / Equity
0.54
Interest cover 13.2x

About Laurus Labs Limited

Data last updated: 25 September 2026

Laurus Labs Limited is a public limited company based in Anakapalle, Andhra Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 19 September 2005, the company has been in operation for over 21 years.

Registered with ROC Vijayawada under CIN L24239AP2005PLC047518. Listed on BSE: 540222 and NSE: LAURUSLABS.

Capital: an authorised share capital of ₹111 Cr and a paid-up capital of ₹108.05 Cr. Formerly known as Aptuit Laurus Limited and Laurus Labs Private Limited. It is led by directors including Venkata Ravi Kumar Vantaram and Satyanarayana Chava.

Last AGM: 26 June 2025. Financial statements filed for year ended 31 March 2025. Office: Anakapalle, Andhra Pradesh.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹6,812.9 Cr, a growth of 22.67% compared to the previous year. The net worth stands at ₹5,300.06 Cr (up 18.5% YoY). Total assets are valued at ₹8,642.03 Cr (up 10.51% YoY).

The company has a workforce of approximately 5,881 employees as per the latest available data. Its group structure includes 4 subsidiaries.

The company is associated with 2 brands - Laurus Labs, Laurus Bio. As per MCA filings, the company has open charges of ₹2,062.31 Cr and satisfied charges of ₹4,004.21 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lauruslabs.com.

Company Details of Laurus Labs Limited
CIN L24239AP2005PLC047518
Registration Number 047518
Incorporation Date 19 September 2005
ROC Vijayawada
Listing Status Listed (BSE: 540222, NSE: LAURUSLABS)
Company Status Active
Date of Last AGM 26 June 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Venkata Ravi Kumar Vantaram Whole-Time Director Satyanarayana Chava Whole-Time Director Venkata Lakshmana Rao Chunduru Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    lauruslabs.com
  • Social Media
  • Registered Address
    Laurus Enclave Plot Office 01 E. Bonangi Village, Parawada (M) Anakapalli District, Anakapalle, Andhra Pradesh, India – 531021
  • Industry
    Pharma, API Manufacturers
Company report
Laurus Labs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Laurus Labs Limited report

Financials, compliance, directors, charges, ownership and filings for Laurus Labs Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Laurus Labs Limited

Laurus Labs Limited has undergone 4 name changes throughout its history. The current legal name is Laurus Labs Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Laurus Labs Limited Current
Aptuit Laurus Limited Previous
Laurus Labs Private Limited Previous
Aptuit Laurus Private Limited Previous

CIN History of Laurus Labs Limited

Laurus Labs Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239AP2005PLC047518, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239AP2005PLC047518 Current
U24239AP2005PTC047518 Previous
U24239AP2005PLC047518 Previous

Associated Brands with Laurus Labs Limited

Laurus Labs Limited operates two associated brands: Laurus Labs and Laurus Bio. These brands represent Laurus Labs Limited's diversified market presence and brand portfolio.

Brand Description Website
Laurus Labs
Pharmaceutical and biotechnology company lauruslabs.com
Laurus Bio
Precision fermentation services for biopharma and food are provided. laurus.bio

Competitors & Alternatives of Laurus Labs Limited

Brands and companies operating in the same space as Laurus Labs Limited include KBI Biopharma, Symbiotec, Aldevron and 7 more.

Competitor Description Location Founded
KBI Biopharma KBI Biopharma Provider of protein formulation, process & cell line development, and cGMP services Durham, United States, United States 1996
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
Aldevron Aldevron Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications Fargo, United States, United States 1998
Ovagen Ovagen Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services Mayo, Ireland, Ireland 2000
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Omnia Biologics Omnia Biologics Process development and manufacturing services for biologics are provided. Rockville, United States, United States 2001
Apicore Apicore APIs are manufactured and custom synthesis services are provided. Somerset, United States, United States 2004
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002
Kemwell Biopharma Kemwell Biopharma Integrated biologics development and manufacturing are provided as a CDMO. Bengaluru, India, India 1980

Business Activity of Laurus Labs Limited

Laurus Labs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Laurus Labs Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Laurus Labs Limited

Laurus Labs Limited is audited by Deloitte Haskins & Sells Llp for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Deloitte Haskins & Sells Llp Locked Locked Locked
Premium access

Complete auditor history for Laurus Labs Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Laurus Labs Limited

Laurus Labs Limited is currently managed by 10 directors, with 21 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Venkata Ravi Kumar Vantaram
Also directs: Laurus Labs Limited, Laurus Bio Private Limited, Krka Pharma Private Limited and 1 more
Whole-Time Director 30 Nov 2006 19 Years 9 Months Current
Satyanarayana Chava
Also directs: Laurus Labs Limited, Immunoadoptive Cell Therapy Private Limited, Laurus Bio Private Limited and 2 more
Whole-Time Director 21 Jan 2006 20 Years 8 Months Current
Venkata Lakshmana Rao Chunduru
Also directs: Laurus Labs Limited, Sriam Labs Private Limited
Whole-Time Director 08 Mar 2018 8 Years 6 Months Current
Rajesh Koshy Chandy
Also directs: Laurus Labs Limited
Director 27 Jul 2016 10 Years 1 Months Current
Aruna Rajendra Bhinge
Also directs: Laurus Labs Limited, Laurus Bio Private Limited, Punjab Chemicals And Crop Protection Limited and 1 more
Director 07 Jul 2016 10 Years 2 Months Current
Ravindranath Kancherla
Also directs: Hygieia Global Health Services Llp, Laurus Labs Limited, Arunachalam Automotives Private Limited and 5 more
Director 18 May 2017 9 Years 4 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Laurus Labs Limited FY 2025-26 filings available

Laurus Labs Limited reported revenue of ₹6,812.9 Cr (up 22.67% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,813 Cr
+22.7% YoY
EBITDA
₹1,778 Cr
+68.5% YoY
Profit After Tax
₹894 Cr
+216.3% YoY
Net Worth
₹5,300 Cr
+18.5% YoY
Total Assets
₹8,642 Cr
+10.5% YoY
Total Debt
₹2,518 Cr
-8.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+11.9%+5.5%-4.2%+26.6%+7.7%+43.9%+17.1%
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Profit before tax1,1824842361,1091,0841,301294
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
Balance sheet
Total assets8,6427,8206,9356,3625,3594,3012,952
Net worth5,3004,4734,1114,0383,3512,5981,770
Total debt2,5182,7642,5772,0151,7771,4821,079
Cash & bank11414414248.4675.9448.461.74
Net working capital2,9892,8492,4402,2461,8041,6441,014
Cash flow
Cash from operations1,624602666994911733347
Cash from investing(1,086)(680)(822)(997)(914)(941)(221)
Cash from financing(525)39.28250(26.64)30.26255(128)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,0261,8121,7781,6531,5701,7201,4151,224
Revenue growth (YoY)+29.1%+5.3%+25.7%+35.1%+31.4%+19.5%+18.4%-0.1%
Other income9.1811.805.7626.9610.4358.579.424.60
EBITDA638512480403382421285178
EBITDA margin+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%+14.6%
Depreciation124122121120117110106108
Interest42.2240.4438.7940.0051.5056.4057.8052.61
Profit before tax48136132727022431213122.81
Tax11979.4673.4575.9863.1478.4740.075.09
Net profit36228225319416123490.6117.72
EPS (₹)6.815.174.653.613.024.331.710.37
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+8.9%+5.2%-5.3%+25.4%+5.0%+46.3%+18.2%
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Profit before tax9945043011,0519751,275304
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
Balance sheet
Total assets7,9057,3086,4325,8965,1784,2552,968
Net worth5,2524,5644,2074,0573,3882,7121,816
Total debt2,0802,3802,1101,7141,6531,4111,051
Cash & bank37.8250.6442.921.7040.5638.780.93
Net working capital2,7332,7632,3482,1861,8441,6991,014
Cash flow
Cash from operations1,385540659882823694345
Cash from investing(847)(592)(757)(735)(837)(900)(217)
Cash from financing(551)59.32139(185)15.19243(127)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,7571,5801,5091,5671,4331,6501,2651,185
Revenue growth (YoY)+22.6%-4.2%+19.3%+32.2%+28.3%+16.7%+11.8%+2.3%
Other income20.0713.0914.3728.4521.5272.167.1211.89
Total expenses1,2581,2051,1641,1771,1051,2551,0591,003
EBITDA499375346390327395206182
EBITDA margin+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%+15.3%
Depreciation95.7695.1794.3195.5993.5788.1988.6690.94
Interest35.2033.9131.4833.6843.8948.6048.0244.69
Profit before tax38825923428921133076.7258.09
Tax98.2167.5859.3673.1753.5078.3019.4515.65

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,0261,8121,7781,6531,5701,7201,4151,224
Revenue growth (YoY)+29.1%+5.3%+25.7%+35.1%+31.4%+19.5%+18.4%-0.1%
Other income9.1811.805.7626.9610.4358.579.424.60
EBITDA638512480403382421285178
EBITDA margin+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%+14.6%
Depreciation124122121120117110106108
Interest42.2240.4438.7940.0051.5056.4057.8052.61
Profit before tax48136132727022431213122.81
Tax11979.4673.4575.9863.1478.4740.075.09
Net profit36228225319416123490.6117.72
EPS (₹)6.815.174.653.613.024.331.710.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+11.9%+5.5%-4.2%+26.6%+7.7%+43.9%+17.1%
Other income54.9575.1026.346.0015.3023.665.92
Total expenses5,0354,4994,2634,4483,5133,2632,267
Employee cost815676615557470397321
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Depreciation480430385324251205187
Interest17121618316510268.1689.59
Profit before tax1,1824842361,1091,0841,301294
Tax29213068.1531225131738.34
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1924,3654,0033,9303,2442,4901,658
Shareholders' funds (net worth)5,3004,4734,1114,0383,3512,5981,770
Minority interest1311304.6211.137.863.150.00
Secured loans1,4251,6741,9281,4251,3731,320875
Unsecured loans1,0931,090649590403161204
Total debt2,5182,7642,5772,0151,7771,4821,079
Total liabilities8,6427,8206,9356,3625,3594,3012,952
Assets
Gross block6,9436,2735,6524,8033,7553,0282,388
Net block4,3714,1233,8903,4092,6522,1711,726
Capital work in progress77345842355181336267.18
Investments30923312449.9030.813.413.41
Inventories2,3421,9371,8451,6851,7601,575905
Sundry debtors2,1552,0071,6631,5801,3541,306791
Cash & bank balances11414414248.4675.9448.461.74
Loans & advances218244185148154145114
Total current assets4,8294,3323,8353,4623,3453,0751,812
Total current liabilities1,8401,4841,3951,2161,5401,431799
Net working capital2,9892,8492,4402,2461,8041,6441,014
Total assets8,6427,8206,9356,3625,3594,3012,952
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash99.5413945.6775.3548.461.692.97
Net cash from operating activities1,624602666994911733347
Net cash from investing activities(1,086)(680)(822)(997)(914)(941)(221)
Net cash from financing activities(525)39.28250(26.64)30.26255(128)
Net change in cash13.12(39.40)93.27(29.68)26.8946.77(1.28)
Closing cash11414414248.4675.9448.461.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%+23.6%
EBITDA growth+68.5%+35.7%-51.2%+11.9%-8.3%+174.7%+58.6%
PBT growth+144.0%+104.9%-78.7%+2.3%-16.7%+343.1%+145.2%
Net income growth+216.3%+74.9%-79.5%-4.6%-15.8%+284.6%+171.1%
Revenue CAGR (3Y)+4.1%+4.0%+1.6%+28.7%+29.1%+32.8%+14.1%
EBITDA CAGR (3Y)+3.7%-9.5%-20.6%+41.3%+58.7%+55.4%+11.5%
Profitability & leverage
Net income margin+13.1%+6.4%+3.3%+13.2%+16.9%+20.4%+9.0%
Return on capital employed+16.7%+8.8%+6.3%+21.8%+24.6%+37.8%+13.6%
Return on net worth+18.2%+6.5%+4.1%+21.6%+28.0%+45.1%+15.3%
Debt / equity0.540.620.560.510.550.590.64
Long-term debt / equity0.150.180.200.190.180.150.13
Interest cover13.1634.5546.5513.028.745.0723.75
Efficiency & per share
Fixed asset turnover1.030.930.961.411.461.781.26
Inventory turnover3.182.942.863.512.963.883.57
Debtors turnover3.273.033.114.123.714.593.77
EPS (₹)16.466.642.9814.6715.4018.3323.88
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)98.1882.9476.2874.9662.3748.41165.11
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,7571,5801,5091,5671,4331,6501,2651,185
Revenue growth (YoY)+22.6%-4.2%+19.3%+32.2%+28.3%+16.7%+11.8%+2.3%
Other income20.0713.0914.3728.4521.5272.167.1211.89
Total expenses1,2581,2051,1641,1771,1051,2551,0591,003
EBITDA499375346390327395206182
EBITDA margin+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%+15.3%
Depreciation95.7695.1794.3195.5993.5788.1988.6690.94
Interest35.2033.9131.4833.6843.8948.6048.0244.69
Profit before tax38825923428921133076.7258.09
Tax98.2167.5859.3673.1753.5078.3019.4515.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+8.9%+5.2%-5.3%+25.4%+5.0%+46.3%+18.2%
Other income77.4310047.4215.9521.5527.325.81
Total expenses4,6514,2734,0634,2923,4223,2592,227
Employee cost684571532478418365300
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Depreciation379359345301235197184
Interest14318215114695.8665.9287.71
Profit before tax9945043011,0519751,275304
Tax25412377.7729122531937.43
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1444,4564,0993,9493,2812,6051,709
Shareholders' funds (net worth)5,2524,5644,2074,0573,3882,7121,816
Secured loans1,0301,3251,4801,1341,2611,257847
Unsecured loans1,0501,054630580392155204
Total debt2,0802,3802,1101,7141,6531,4111,051
Total liabilities7,9057,3086,4325,8965,1784,2552,968
Assets
Gross block5,3654,8794,7064,2223,2542,6572,341
Net block3,0412,8883,0362,8842,1861,8181,694
Capital work in progress56933615635775532466.53
Investments89174063538436231958.32
Inventories2,1361,7391,6971,5691,6891,534893
Sundry debtors2,0232,0351,6401,4871,2691,280778
Cash & bank balances37.8250.6442.921.7040.5638.780.93
Loans & advances165182137113206189112
Total current assets4,3634,0073,5173,1713,2053,0411,785
Total current liabilities1,6301,2431,1709861,3601,343771
Net working capital2,7332,7632,3482,1861,8441,6991,014
Total assets7,9057,3086,4325,8965,1784,2552,968
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash50.3642.631.4240.3338.780.880.51
Net cash from operating activities1,385540659882823694345
Net cash from investing activities(847)(592)(757)(735)(837)(900)(217)
Net cash from financing activities(551)59.32139(185)15.19243(127)
Net change in cash(12.85)7.7341.21(38.91)1.5537.900.37
Closing cash37.8250.6442.921.7040.5638.780.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%+25.1%
EBITDA growth+52.3%+25.9%-49.4%+15.3%-14.9%+164.8%+62.3%
PBT growth+97.3%+67.1%-71.3%+7.8%-23.5%+318.6%+151.2%
Net income growth+144.2%+35.8%-70.5%+1.3%-21.5%+257.4%+180.0%
Revenue CAGR (3Y)+1.8%+3.5%+0.3%+27.3%+28.2%+33.0%+13.9%
EBITDA CAGR (3Y)-1.0%-9.8%-20.8%+37.5%+54.1%+54.6%+11.3%
Profitability & leverage
Net income margin+12.2%+7.3%+4.7%+13.2%+15.9%+20.1%+9.6%
Return on capital employed+15.0%+9.1%+7.3%+21.6%+22.7%+37.1%+13.9%
Return on net worth+15.1%+6.9%+5.4%+20.4%+24.6%+42.2%+15.7%
Debt / equity0.450.510.460.450.500.540.60
Long-term debt / equity0.090.110.140.160.160.130.13
Interest cover13.4931.1237.2512.349.135.0222.70
Efficiency & per share
Fixed asset turnover1.191.091.081.541.591.911.27
Inventory turnover3.143.042.953.542.923.933.59
Debtors turnover3.002.843.084.193.694.633.82
EPS (₹)13.727.054.1514.1213.9617.8224.98
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)97.2984.6478.0675.3163.0550.54169.84
Want more history and ratios?
You're viewing the latest exchange-filed financials for Laurus Labs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Laurus Labs Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 27.50%, foreign institutional investors hold 28.00%, domestic institutional investors hold 13.70%, retail and other public shareholders hold 30.80% of Laurus Labs Limited.

Promoters: 27.50%DII (Domestic Institutional): 13.70%FII (Foreign Institutional): 28.00%Retail & Others: 30.80%
Jun 2026
QUARTER
27.50% Promoters
13.70% DII (Domestic Institutional)
28.00% FII (Foreign Institutional)
30.80% Retail & Others
Promoter holding - history
Now 27.50% · Jun 2026High 27.60% · Sep 2025Low 27.50% · Dec 2025
26%26.8%27.5%28.3%29%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 27.60%Dec 2025: 27.50%Mar 2026: 27.50%Jun 2026: 27.50%27.60%27.50%27.50%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters27.50%27.50%27.50%27.60%
Public72.50%72.50%72.50%72.40%

Group Structure of Laurus Labs Limited

Laurus Labs Limited has 4 subsidiary companies and 2 associated companies. This group structure data is as of FY 2023. The corporate group structure reflects Laurus Labs Limited's business expansion strategy and organizational complexity.

4
Subsidiary companies
2
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Laurus Bio Private Limited U02423KA2005PTC036770 -
Laurus Synthesis Private Limited U24110TG2020PTC140333 -
Laurus Specialty Chemicals Private Limited U24110TG2022PTC168791 -
Sriam Labs Private Limited U24239TG2002PTC038490 -

Showing major subsidiaries. Total: 4.

Charges & Borrowings of Laurus Labs Limited

Open charges
₹2,062.31 Cr
Satisfied charges
₹4,004.21 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹1,604.31 Cr
Others₹458.00 Cr
Latest charge details
DateLenderAmountStatus
18 Feb 2026 Others ₹200 Cr Open
29 Aug 2024 Others ₹258 Cr Open
16 May 2022 Sbicap Trustee Company Limited ₹1,604.31 Cr Open
21 Mar 2025 Others ₹200 Cr Satisfied
06 Dec 2023 Hdfc Bank Limited ₹200 Cr Satisfied

Total charge records: 38 View all charges

Employees and EPFO Compliance at Laurus Labs Limited

Laurus Labs Limited has a workforce of 5,881 employees as of Apr 09, 2024.

Employee count
5,881
Active EPFO establishments
1
Employee growth
4.55%
Premium access

Employee and EPFO history for Laurus Labs Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Laurus Labs Limited

Premium access

GST registrations and filing compliance for Laurus Labs Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Laurus Labs Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Laurus Labs Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Laurus Labs Limited

Premium access

MSME payment history for Laurus Labs Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Laurus Labs Limited

Premium access

Corporate group structure for Laurus Labs Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Laurus Labs Limited

Premium access

MCA filings and documents for Laurus Labs Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Laurus Labs Limited

Charges
18 Feb 2026
A charge with Others amounted to Rs. 200.00 Cr with Charge ID 101238887 was registered on 18 Feb 2026.
Charges
17 Feb 2026
A charge registered on 21 Mar 2025 via Charge ID 101064181 with Others was fully satisfied on 17 Feb 2026.
Charges
24 Sep 2025
A charge with Sbicap Trustee Company Limited of Rs. 1,604.31 Cr registered on 16 May 2022 with Charge ID 100574403 was modified on 24 Sep 2025.
Activity
26 Jun 2025
Laurus Labs Limited last Annual general meeting of members was held on 26 Jun 2025 as per latest MCA records.
Activity
31 Mar 2025
Laurus Labs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Vijayawada.
Charges
21 Mar 2025
A charge with Others amounted to Rs. 200.00 Cr with Charge ID 101064181 was registered on 21 Mar 2025.

Recent News on Laurus Labs Limited

Frequently Asked Questions about Laurus Labs Limited

Laurus Labs Limited is an active public limited company in the pharma sector based in Anakapalle, Andhra Pradesh, India. It was incorporated on 19 September 2005 (21+ years old) and is registered under CIN L24239AP2005PLC047518. Listed on BSE: 540222 and NSE: LAURUSLABS. The company has 5,881 employees.

Laurus Labs Limited reported revenue of ₹6,812.9 Cr for FY 2025-26 (up 22.67% YoY) based on consolidated financials.

The current directors of Laurus Labs Limited are:

The primary industry of Laurus Labs Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Laurus Labs Limited is listed on both BSE (code: 540222) and NSE (symbol: LAURUSLABS).

Laurus Labs Limited can be reached at the registered office: Laurus Enclave Plot Office 01 E. Bonangi Village, Parawada M Anakapalli District, Anakapalle, Andhra Pradesh, India – 531021, or through the website lauruslabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available